Abstract
Rose Bengal is a novel injectable agent that has been evaluated as a rational treatment strategy for melanoma patients with recurrent unresectable local/regional metastases accessible for intralesional injection. PV-10 (10% Rose Bengal) has completed phase 1 and phase 2 multi-center clinical trials demonstrating significant local/regional disease control and also responses in non-injected regional bystander lesions and distant metastases. The published results of studies that have assessed PV-10 are presented, and the rationale for combining its use with recently approved immunotherapeutic agents is discussed. J. Surg. Oncol. 2014 109:314-319.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 314-319 |
| Number of pages | 6 |
| Journal | Journal of surgical oncology |
| Volume | 109 |
| Issue number | 4 |
| DOIs | |
| State | Published - Mar 2014 |
Keywords
- intralesional therapy
- melanoma
- treatment
ASJC Scopus subject areas
- Surgery
- Oncology
MD Anderson CCSG core facilities
- Clinical and Translational Research Center
- Clinical Trials Office